$CHEV
Charging Robotics Inc. Stock $chev

$chev Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000121390023086069 Filed on November 13, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q4
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$227.0K	$127.0K
YoY Change
% of Gross Profit
Research & Development	$9.000K	$145.0K
YoY Change		-31.92%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$236.0K	$145.0K
YoY Change		290.81%
Operating Profit		-$272.0K
YoY Change		633.11%
Interest Expense	-$14.00K	-$14.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$250.0K	-$286.0K
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	-$250.0K	-$286.0K
YoY Change		670.85%
Net Earnings / Revenue
Basic Earnings Per Share		$0.00
Diluted Earnings Per Share	-$0.03	$0.00
COMMON SHARES
Basic Shares Outstanding	1.373B shares	1.373B shares	256.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.000K	$111.0K
YoY Change
Cash & Equivalents	$8.000K	$111.0K	$107.1K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$51.00K	$157.0K	$107.1K
YoY Change	-52.36%	44.1%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles	$100.0K	$85.00K	$74.00K
YoY Change	35.14%		0.0%
Long-Term Investments	$110.0K	$106.0K
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$272.0K	$252.0K	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$51.00K	$157.0K	$107.1K
Total Long-Term Assets	$272.0K	$252.0K	$0.00
Total Assets	$323.0K	$409.0K	$107.1K
YoY Change	201.69%	275.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$104.0K	$74.00K	$52.14K
YoY Change	99.45%	170.07%	176.52%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$30.00K	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$348.0K	$190.0K	$55.14K
YoY Change	531.08%	-0.21%	192.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$49.00K	$49.00K
YoY Change
Total Long-Term Liabilities	$49.00K	$49.00K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$348.0K	$190.0K	$55.14K
Total Long-Term Liabilities	$49.00K	$49.00K
Total Liabilities	$397.0K	$239.0K	$55.14K
YoY Change	619.93%	25.53%	192.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.966M	-$1.716M	-$1.660M
YoY Change	18.45%	5.92%	6.56%
Common Stock	$137.0K	$1.818M	$31.44K
YoY Change	335.74%	6981.09%	22.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$74.00K	$170.0K	$51.92K
YoY Change
Total Liabilities & Shareholders Equity	$323.0K	$409.0K	$107.1K
YoY Change	201.69%	275.4%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$250.0K	-$286.0K
YoY Change		670.85%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$106.0K	-$511.0K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures	$26.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$3.000K
YoY Change
Cash From Investing Activities	-$26.00K	$3.000K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	30.00K	591.0K
YoY Change
NET CHANGE
Cash From Operating Activities	-106.0K	-511.0K
Cash From Investing Activities	-26.00K	3.000K
Cash From Financing Activities	30.00K	591.0K
Net Change In Cash	-102.0K	83.00K
YoY Change
FREE CASH FLOW
Cash From Operating Activities	-$106.0K	-$511.0K
Capital Expenditures	$26.00K
Free Cash Flow	-$132.0K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-28.36
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-56253
	dei	Entity Registrant Name EntityRegistrantName	FUEL DOCTOR HOLDINGS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2274999
	dei	Entity Address Address Line1 EntityAddressAddressLine1	20 Raul Wallenberg Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Tel Aviv
	dei	Entity Address Country EntityAddressCountry	IL
	dei	City Area Code CityAreaCode	(647)
	dei	Local Phone Number LocalPhoneNumber	558-5564
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1372656029	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	111000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27000	usd
CY2023Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	46000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	71000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	157000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	98000	usd
CY2023Q3	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	106000	usd
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	152000	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	85000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	74000	usd
CY2023Q3	fdoc	Shareholder Loan ShareholderLoan	61000	usd
CY2022Q4	fdoc	Shareholder Loan ShareholderLoan	60000	usd
CY2023Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	252000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	286000	usd
CY2023Q3	us-gaap	Assets Assets	409000	usd
CY2022Q4	us-gaap	Assets Assets	384000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	74000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	108000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	595000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	43000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	190000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	703000	usd
CY2023Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	49000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	49000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	239000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	752000	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2990000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1372656029	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1372656029	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2990000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27273	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27273	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	137000	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1681000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	741000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-32000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-12000	usd
CY2023Q3	fdoc	Reserve From Sharebased Compensation Transactions ReserveFromSharebasedCompensationTransactions	100000	usd
CY2022Q4	fdoc	Reserve From Sharebased Compensation Transactions ReserveFromSharebasedCompensationTransactions	91000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1716000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1188000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	170000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-368000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	409000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	384000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	145000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	213000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	294000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	577000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	127000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	210000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	131000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-272000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-252000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-504000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-708000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-272000	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-252000	usd
	us-gaap	Profit Loss ProfitLoss	-504000	usd
	us-gaap	Profit Loss ProfitLoss	-708000	usd
CY2023Q3	fdoc	Share In Losses Of Affiliate ShareInLossesOfAffiliate	-14000	usd
CY2022Q3	fdoc	Share In Losses Of Affiliate ShareInLossesOfAffiliate	-33000	usd
	fdoc	Share In Losses Of Affiliate ShareInLossesOfAffiliate	-24000	usd
	fdoc	Share In Losses Of Affiliate ShareInLossesOfAffiliate	-42000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-286000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-285000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-528000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-750000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-20000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-20000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-24000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-306000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-284000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-548000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-774000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-10.45
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-27.5
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1372656029	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27273	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	869445617	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27273	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	450000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-752000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-291000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-368000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	100000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	509000	usd
	fdoc	Effect Of Reverse Merger EffectOfReverseMerger	-24000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	501000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-548000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	170000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-528000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-750000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	11000	usd
	fdoc	Share In Losses Of Affiliates ShareInLossesOfAffiliates	24000	usd
	fdoc	Share In Losses Of Affiliates ShareInLossesOfAffiliates	42000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-25000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	38000	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-26000	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-326000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-99000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	237000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	32000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	142000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	50000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-511000	usd
	fdoc	Effect Of Reverses Merger EffectOfReversesMerger	3000	usd
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	6000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	61000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-67000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	500000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	91000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	591000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	83000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-47000	usd
CY2023Q3	fdoc	Effect Of Changes In Foreign Exchange Rates EffectOfChangesInForeignExchangeRates	1000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	167000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	65000	usd
	fdoc	Decrease In Related Party Balances DecreaseInRelatedPartyBalances	40000	usd
	fdoc	Investment In Intangible Asset InvestmentInIntangibleAsset	509000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1188000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1716000	usd
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.1999	pure
CY2022Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	340000	usd
CY2022Q3	us-gaap	Participating Mortgage Loans Participation Liabilities Amount ParticipatingMortgageLoansParticipationLiabilitiesAmount	1000000	usd
CY2023Q3	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	61000	usd
CY2023Q1	us-gaap	Shares Issued SharesIssued	921750000	shares
CY2023Q3	us-gaap	Shares Issued SharesIssued	921750000	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	922500000	shares
CY2023Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	136500000	shares
CY2023Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	500000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of estimates:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to shares based compensation and Going concern.</span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration of credit risks:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and restricted bank deposit. Cash and cash equivalents and restricted bank deposit are invested in major banks in Israel and the United States. Such funds in the Israel may be in excess of insured limits and are not insured in other jurisdictions. Management believes that the financial institutions that hold the Company and its subsidiary’ cash and cash equivalents have high credit ratings.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company, have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></p>
CY2021Q4	fdoc	Investment In Affiliated Balance Beginning InvestmentInAffiliatedBalanceBeginning	217000	usd
CY2022	fdoc	Share In Loss Of Affiliates ShareInLossOfAffiliates	-42000	usd
CY2022	us-gaap	Realized Gain Loss Investment Derivative And Foreign Currency Transaction Operating After Tax RealizedGainLossInvestmentDerivativeAndForeignCurrencyTransactionOperatingAfterTax	-23000	usd
CY2023Q3	us-gaap	Defined Benefit Plan Funded Percentage DefinedBenefitPlanFundedPercentage	0.50	pure
CY2022Q4	fdoc	Investment In Affiliated Balance Ending InvestmentInAffiliatedBalanceEnding	152000	usd
	fdoc	Share In Loss Of Affiliates ShareInLossOfAffiliates	-24000	usd
	us-gaap	Realized Gain Loss Investment Derivative And Foreign Currency Transaction Operating After Tax RealizedGainLossInvestmentDerivativeAndForeignCurrencyTransactionOperatingAfterTax	-22000	usd
CY2023Q3	fdoc	Investment In Affiliated Balance Ending InvestmentInAffiliatedBalanceEnding	106000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P20Y
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	74000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	74000	usd
	us-gaap	Additions To Other Assets Amount AdditionsToOtherAssetsAmount	11000	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	85000	usd
CY2023Q3	fdoc	Total Related Parties TotalRelatedParties	73000	usd
CY2022Q4	fdoc	Total Related Parties TotalRelatedParties	595000	usd
CY2023Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	550000	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.0242	pure
	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	Pursuant to the Medigus Loan Agreement, the interest rate remains unchanged, and the capital and interest was to be repaid in cash or shares, or a combination thereof by June 30, 2023. On April 4, 2023, the Medigus Loan balance owing was $553. $509 of the Medigus Loan was converted into 28 shares of Charging Robotics and the remaining Medigus Loan balance will be repaid in cash.
CY2021Q4	fdoc	Related Party Fee Expense RelatedPartyFeeExpense	24700	ils
CY2021Q4	fdoc	Related Party Fee Expense RelatedPartyFeeExpense	7000	usd
CY2021Q4	fdoc	Stock Options Percentage StockOptionsPercentage	0.03	pure
CY2021Q4	us-gaap	Deferred Taxes Business Combination Valuation Allowance Allocated To Contributed Capital DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital	10000000	usd
	fdoc	Chief Executive Officer Income ChiefExecutiveOfficerIncome	63000	usd
	fdoc	Chief Executive Officer Income ChiefExecutiveOfficerIncome	66000	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2990000000	shares
CY2023Q3	fdoc	Common Stock Shares Issued And Outstanding CommonStockSharesIssuedAndOutstanding	1372656029	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2990000000	shares
CY2022Q4	fdoc	Common Stock Shares Issued And Outstanding CommonStockSharesIssuedAndOutstanding	27273	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	fdoc	Percentage Of Shares Issued And Outstanding PercentageOfSharesIssuedAndOutstanding	0.7288	pure
CY2023Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	91000	usd
CY2023Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	28	shares
CY2023Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	7636	shares
CY2023Q2	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	501000	usd
CY2023Q2	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding	205898404	shares
	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	(i) change its name to Charging Robotics Inc. (the “Name Change”); and (ii) effect a one-for-one hundred fifty reverse stock split (the “Reverse Stock Split”) of its outstanding shares of Common Stock.
CY2022Q1	fdoc	Stock Options Granted StockOptionsGranted	30000	usd
CY2022Q1	us-gaap	Share Price SharePrice	7410
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0048	pure
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.75	pure
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	18	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8333
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	22	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6818
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	18	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8333
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	22	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	18	shares
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	73000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2023Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense		usd
CY2022Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense		usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense		usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense		usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	20000	usd
	fdoc	Effect Of Reverses Merger EffectOfReversesMerger		usd
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022Q3	fdoc	Effect Of Changes In Foreign Exchange Rates EffectOfChangesInForeignExchangeRates		usd
	fdoc	Franchise Taxes FranchiseTaxes		usd
	fdoc	Franchise Taxes FranchiseTaxes		usd
	fdoc	Investment In Intangible Asset InvestmentInIntangibleAsset		usd
CY2022	us-gaap	Additions To Other Assets Amount AdditionsToOtherAssetsAmount		usd
CY2023Q3	fdoc	Preferred Shares Issued And Outstanding PreferredSharesIssuedAndOutstanding		shares
CY2022Q4	fdoc	Preferred Shares Issued And Outstanding PreferredSharesIssuedAndOutstanding		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber		shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	00000
	dei	Entity Central Index Key EntityCentralIndexKey	0001459188

Files In Submission

Name	View Source	Status
0001213900-23-086069-index-headers.html	Edgar Link	pending
0001213900-23-086069-index.html	Edgar Link	pending
0001213900-23-086069.txt	Edgar Link	pending
0001213900-23-086069-xbrl.zip	Edgar Link	pending
f10q0923ex31-1_fueldoc.htm	Edgar Link	pending
f10q0923ex31-2_fueldoc.htm	Edgar Link	pending
f10q0923ex32-1_fueldoc.htm	Edgar Link	pending
f10q0923ex32-2_fueldoc.htm	Edgar Link	pending
f10q0923_fueldoctor.htm	Edgar Link	pending
fdoc-20230930.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
fdoc-20230930_def.xml	Edgar Link	unprocessable
fdoc-20230930_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
fdoc-20230930_pre.xml	Edgar Link	unprocessable
f10q0923_fueldoctor_htm.xml	Edgar Link	completed
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
fdoc-20230930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CHEV
Charging Robotics Inc. Stock $chev

2023 Q4 Form 10-Q Financial Statement

#000121390023086069 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHEV Charging Robotics Inc. Stock $chev

2023 Q4 Form 10-Q Financial Statement

#000121390023086069 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHEV
Charging Robotics Inc. Stock $chev